1 / 6

What Investors in Pharma and Biotech are Looking for (and how to Meet those Expectations)

What Investors in Pharma and Biotech are Looking for (and how to Meet those Expectations). NSEP 1 st March 2005. Value Creation. Security Growth. Mentoring. Investors. Biotech. Newsflow pre and post funding. Confidence from  clinical success  roll out products  sales  value

PamelaLan
Télécharger la présentation

What Investors in Pharma and Biotech are Looking for (and how to Meet those Expectations)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. What Investors in Pharma and Biotech are Looking for(and how to Meet those Expectations) NSEP 1st March 2005

  2. Value Creation Security Growth Mentoring Investors Biotech Newsflow pre and post funding • Confidence from •  clinical success •  roll out products •  sales •  value •  efficiency on cash burn • Constraints • 30% have < 2 years cash • Management team • Reach

  3. Proof of Value • Point at which proof of value obtained is dependent upon: • Class of compound; is it well validated or unknown? • Ability of animal models utilised to predict human efficacy • Presence of validated surrogate marker or endpoint- how early in development can these be used to demonstrate effect? • Whether sufficient just to show that does not have the significant pharmacological AE’s of current treatments • Demonstration of developability

  4. Proof of Value:Alternative definitions

  5. Proof of Value Supply and demand pressure on Pharma to in license earlier Supply Value Unknown, unvalidated class Known, validated class Pressure on Biotech to license out earlier for validation Demand Risk II III I First Dose in Man Proof of Principle Proof of Concept

  6. However as a young Biotech are you… • Sustainable or just following fashion? • “hot agonist/antagonist” of the day • Selling the crown jewels? • Leaving enough in the pipeline to create value in the future? • Able to produce fuel/cash until the end game?

More Related